DMR-001 (mutant CALR-targeted antibody)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-30 — Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies in CALR-mutant Myeloproliferative Neoplasms: Phase 1/1b first-in-human trial (trial-early) formally underway evaluating DMR-001 safety, PK, immunogenicity, and preliminary efficacy as monotherapy in CALR-mutant ET and MF, and in combination with ruxolitinib in CALR-mutant MF. (novelty: 4)
Open questions
Related
Contributing findings
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies in CALR-mutant Myeloproliferative Neoplasms
30-sep-2026
novelty 4
per-area 4
introduces